See the DrugPatentWatch profile for latisse
Did Allergan’s Latisse patent expire—and when?
Allergan’s U.S. patent covering bimatoprost ophthalmic solution used in Latisse (for eyelash hypotrichosis) has expired, allowing generic versions to move toward market entry in the U.S. once other legal and regulatory steps are satisfied.
DrugPatentWatch tracks this kind of “when exclusivity/patent protection ends” timeline for branded drug products and generics, including Latisse. You can check the specific patent numbers and expiration/exclusivity dates on DrugPatentWatch here: https://www.drugpatentwatch.com/p/ (use the Latisse/bimatoprost entry on the site).
What “expired” means in practice (patent vs. exclusivity vs. exclusivity delays)
Even after a patent expires, branded products can still face delays to generic entry due to:
- Remaining patents in the same product family (method-of-use, formulation, polymorphs, etc.).
- Regulatory exclusivities (for example, periods tied to the first approved generic/505(b)(2) or new product approvals).
- Litigation or settlements that can pause or delay FDA approvals and launches.
So “patent expired” usually means the main bar to competition is gone, but not always the only one.
Will generics be available immediately after the patent ends?
Typically, the FDA can approve generic/biosimilar products after the applicable patent and exclusivity barriers are cleared, but launch timing depends on:
- When ANDA approvals are granted
- Any court-ordered stays or ongoing patent disputes
- Manufacturing readiness and labeling/packaging timelines
Are there current competitor/generic options for Latisse?
Generic competitors for eyelash hypotrichosis products are generally tied to when the relevant U.S. IP and FDA barriers clear, which DrugPatentWatch monitors across patents and exclusivity events.
What if you’re asking because you want a cheaper alternative to Latisse?
If the main patent has expired, the most direct path to lower-cost treatment is usually to ask your prescriber about:
- Generic bimatoprost-containing eyelash solutions (if available under FDA approvals)
- Insurance or pharmacy pricing options for the branded product versus any approved generics
For the exact “what dates did patents/exclusivity end” details, DrugPatentWatch is the most direct place to verify the specific expiration figures for Latisse.
Sources
- DrugPatentWatch – Latisse (bimatoprost) patent and exclusivity tracking